Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Revenue (2019 - 2025)

Keros Therapeutics filings provide 6 years of Revenue readings, the most recent being $577000.0 for Q4 2025.

  • On a quarterly basis, Revenue rose 213.58% to $577000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $244.3 million, a 203644.17% increase, with the full-year FY2025 number at $244.1 million, changed N/A from a year prior.
  • Revenue hit $577000.0 in Q4 2025 for Keros Therapeutics, down from $14.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $211.2 million in Q1 2025 to a low of -$508000.0 in Q4 2024.
  • Median Revenue over the past 5 years was $577000.0 (2025), compared with a mean of $25.5 million.
  • The widest YoY moves for Revenue: up 4750.0% in 2024, down 455.24% in 2024.
  • Keros Therapeutics' Revenue stood at $17.9 million in 2021, then rose by 0.56% to $18.0 million in 2022, then plummeted by 99.21% to $143000.0 in 2023, then tumbled by 455.24% to -$508000.0 in 2024, then soared by 213.58% to $577000.0 in 2025.
  • The last three reported values for Revenue were $577000.0 (Q4 2025), $14.3 million (Q3 2025), and $18.2 million (Q2 2025) per Business Quant data.